Author:
du Bois A.,Burges A.,Meier W.,Pfisterer J.,Schmalfeldt B.,Richter B.,Jackisch C.,Staehle A.,Kimmig R.,Elser G.
Reference9 articles.
1. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer; the ICON4/AGO-OVAR-2.2 trial;Lancet,2003
2. Gemcitabine/carboplatin (GC) vs carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA) Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR the NCIC CTG and the EORTC GCG;Pfisterer;Proc Am Soc Clin Oncol,2004
3. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian cancer. A multicenter GINECO phase II study;Guastalla;Ann Oncol,1998
4. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer (abstract 808);O'Byrne;Proc Am Soc Clin Oncol,2002
5. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus toptecan;Gordon;J Clin Oncol,2001
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献